Quinone reductase 2 and aldehyde dehydrogenase as therapeutic targets
OwnerTimothy A. Haysteadinventor
Life of this patent
Estimating the term…
Abstract
The present invention relates, in general, to quinone reductase 2 (QR2) and aldehyde dehydrogenase (ALDH), and, in particular, to methods of screening compounds for their ability to modulate the activity of QR2 and/or ALDH and thereby to function as anti-malarial, anti-arthritic and/or anti-lupus agents. The invention further relates to the use of compounds that inhibit ALDH in the production of stem cells en masse.
Claims22
A method of screening a test compound for its potential as a therapeutic in a medical indication amenable to treatment with a chloroquine-based drug comprising:
- i) contacting said test compound and quinone reductase 2 (QR2), or portion thereof, or fusion protein comprising said QR2 or said portion thereof,
- ii) determining the amount of said test compound bound to said QR2, or said portion thereof or said fusion protein,
- wherein a test compound that binds QR2, or said portion thereof or said fusion protein, is potentially useful for the treatment of said medical indication.
A method of screening a test compound for its potential as a therapeutic in a medical indication amenable to treatment with a chloroquine-based drug comprising:
- i) contacting said test compound and aldehyde dehydrogenase (ALDH), or portion thereof or fusion protein comprising said ALDH or said portion thereof,
- ii) determining the amount of said test compound bound to said ALDH, or said portion thereof or said fusion protein,
- wherein a test compound that binds ALDH, or said portion thereof or said fusion protein, is potentially useful for the treatment of said medical indication.
A method of screening a test compound for its potential as a therapeutic in a medical indication amenable to treatment with a chloroquine-based drug comprising:
- i) contacting QR2, or portion thereof or fusion protein comprising said QR2 or said portion thereof, with an agent known to bind thereto, under conditions such that said agent can bind to said QR2, or said portion thereof or said fusion protein, wherein said contacting is effected in the presence and absence of said test compound, and
- ii) determining the amount of said agent bound to said QR2, or said portion thereof or said fusion protein, in the presence and absence of said test compound,
- wherein a reduction in the amount of said agent bound to said QR2, or said portion thereof or said fusion protein, in the presence of said test compound indicates that said test compound has potential as a therapeutic in said medical indication.
A method of screening a test compound for its potential as a therapeutic in a medical indication amenable to treatment with a chloroquine-based drug comprising:
- i) contacting ALDH, or portion thereof or fusion protein comprising said ALDH or said portion thereof, with an agent known to bind thereto, under conditions such that said agent can bind to said ALDH, or said portion thereof or said fusion protein, wherein said contacting is effected in the presence and absence of said test compound, and
- ii) determining the amount of said agent bound to said ALDH, or said portion thereof or said fusion protein, in the presence and absence of said test compound,
- wherein a reduction in the amount of said agent bound to said ALDH, or said portion thereof or said fusion protein, in the presence of said test compound indicates that said test compound has potential as a therapeutic in said medical indication.
Dependencies are inferred from the claim text.